Worldwide Epidemiology of Neutralizing Antibodies to Adeno-Associated Viruses
By R. Calcedo, L. Vandenberghe, G. Gao, Jian-ping Lin, James M. Wilson. Journal of Infectious Diseases, 2009
789 citations recorded by the source corpus.
Recombinant adeno-associated viruses (AAVs) have unique gene-transfer properties that speak to their potential as carriers for gene therapy or vaccine applications. However, the presence of neutralizing antibodies to AAV as a result of previous exposure can significantly limit effective gene transfer. In this study, we obtained 888 human serum samples from healthy volunteers in 10 countries around the world. Samples were assayed for neutralizing antibodies to AAV1, AAV2, AAV7, and AAV8, as well as to a novel, structurally distinct AAV vector, rh32.33, in an in vitro transduction inhibition assay. Our data revealed that neutralizing antibodies to AAV2 were the most prevalent antibodies in all regions, followed by antibodies to AAV1. The seroprevalences of antibodies to AAV7 and to AAV8 were lower than that for antibodies to AAV1, and neutralization of AAVrh32.33 was only rarely detected. Our data also indicate a strong linkage of seroreactivity between apparently distinct serotypes that has not been predicted previously in animal models.
Subfields: Cardiology and Cardiovascular Medicine, Genetics, Oncology
View Paper: https://www.semanticscholar.org/paper/0a51f86b06b98c25c24eea37fe2be9d79c0f7e53
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Genetics
Citations in the corpus
- Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors (2010, neutral): “5%) neutralizing factors, as previously reported in Europe with about 55 and 46%, respectively (Calcedo et al., 2009).”
- Adeno-associated virus as a delivery vector for gene therapy of human diseases (2024, background): “26 Another study showed that the most prevalent NAbs against serotypes other than AAV2 in serum from 552 human samples were AAV1 (74.9%), AAV6 (70.1%), AAV5 (63.9%), AAV8 (60.4%), and AAV9 (57.8%).”
- Immune responses to AAV vectors: overcoming barriers to successful gene therapy. (2013, neutral): “40 Switch AAV serotype 62 or engineer AAV capsids that are less susceptible to NAb.”